Company

Pulmonx Corporation

Headquarters: Redwood City, CA, United States

Employees: 253

CEO: Mr. Glendon E. French

NASDAQ: LUNG +3.71%

Market Cap

$251.9 Million

USD as of July 1, 2024

Market Cap History

Pulmonx Corporation market capitalization over time

Evolution of Pulmonx Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Pulmonx Corporation

Detailed Description

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Pulmonx Corporation has the following listings and related stock indices.


Stock: NASDAQ: LUNG wb_incandescent

Details

Headquarters:

700 Chesapeake Drive

Redwood City, CA 94063

United States

Phone: 650-364-0400

Fax: 650-364-0403